Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620074 · ClinicalTrials.gov registry record · Phase 4
Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)
A Phase 4 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00620074 is a Phase 4 study that was terminated before completion, run by Pfizer. The registered enrollment target is 6 participants.
The verdict
NCT00620074, a Phase 4 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate polyene therapy.
Interventions
- DRUG voriconazole
- DRUG anidulafungin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00620074
The ClinicalTrials.gov registry entry for NCT00620074 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which voriconazole is the first listed.
NCT00620074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00620074 about?
NCT00620074 is a clinical study titled "Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)". This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate polyene therapy.
What is the current status of trial NCT00620074?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2008-08. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00620074?
The interventions under investigation include: voriconazole (DRUG), anidulafungin (DRUG).
Who is sponsoring clinical trial NCT00620074?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.